Herpes Zoster Vaccine

• 

  Subject Areas on Research

  • A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. 
  • A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation. 
  • Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. 
  • Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults. 
  • Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. 
  • Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations. 
  • Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. 
  • Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. 
  • Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. 
  • Herpes Zoster Vaccination: Controversies and Common Clinical Questions. 
  • Herpes Zoster. 
  • Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. 
  • Long-term persistence of zoster vaccine efficacy. 
  • Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine. 
  • Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. 
  • Perspective on live varicella vaccine. 
  • Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. 
  • Safety of zoster vaccine in elderly adults following documented herpes zoster. 
  • The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. 
  • The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. 
  • The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. 
  • Update on immunizations in adults. 
  • Vaccination against Herpes Zoster and Postherpetic Neuralgia. 
  • Vaccination against herpes zoster in developed countries: state of the evidence. 
  • Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. 
  • Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.